Key result
Carbimazole and ivabradine prompt remarkable recovery in a case of thyrotoxic cardiomyopathy.
Case Report (n=1)
This case highlights the successful management of thyrotoxic cardiomyopathy complicated by atrial fibrillation and systolic impairment using carbimazole and ivabradine.
Should not change practice in thyrotoxic cardiomyopathy; leaves open a possible adjunctive role for ivabradine with antithyroid therapy.
We present the case of a 65-year-old woman who was referred urgently from primary care with worsening breathlessness for 3 weeks, associated with tachycardia and left bundle branch block (LBBB). She had a background of type 2 diabetes, asthma and hypertension. Initial ECG revealed atrial fibrillation with the fast ventricular rate on the background of LBBB. ECHO findings were consistent with systolic impairment. Initial testing including checking thyroid function test revealed hyperthyroidism. It became evident that this patient had thyrotoxic cardiomyopathy. Early advice from the endocrine team was sought and the patient was treated with a combination of carbimazole and ivabradine. After a hospital stay, she made a remarkable recovery.
No takes yet. Share an insight, caveat, or question.
Alam et al. (2019) conducted a case report in Thyrotoxic cardiomyopathy (n=1). Carbimazole and ivabradine was evaluated on Recovery. Treatment with carbimazole and ivabradine led to a remarkable recovery in a 65-year-old woman with thyrotoxic cardiomyopathy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: